Previous 10 | Next 10 |
Interim Analysis Findings Support Continued Evaluation of Both Monotherapy and Combination Therapy Encouraging Efficacy Results Include Independently Confirmed Responses in Both KRAS Mutant and KRAS Wild-Type Tumors with No New Safety Signals Observed Substantial Major...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
3 Penny Stocks to Add to Your Watchlist in June 2022 Finding penny stocks to buy can be challenging. With so much going on in the stock market, it can be hard to know where to start. These days, there are plenty of resources available to help you find penny stocks to buy. However, n...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Verastem Oncology (NASDAQ:VSTM) said it was selected to receive the first Therapeutic Accelerator Award of $3.8M from the Pancreatic Cancer Network (PanCAN). The Needham, Mass.-based company added that the award will support a phase 1b/2 trial of its lead candidates VS-6766 and defactini...
Award to Conduct Phase 1b/2 Clinical Trial of VS-6766 and Defactinib Combination in Addition to Standard of Care Chemotherapy with Objective of Increasing Response Rate and Survival Trial to Evaluate a Promising Approach for More Complete Blockade of Tumorigenic Signaling ...
Verastem press release (NASDAQ:VSTM): Q1 Non-GAAP EPS of -$0.08 beats by $0.01. Revenue of $2.6M (+157.4% Y/Y) beats by $1.1M. For further details see: Verastem Non-GAAP EPS of -$0.08 beats by $0.01, revenue of $2.6M beats by $1.1M
Enrollment Completed in Selection Phases (Part A) of RAMP 201 and RAMP 202 Evaluating VS-6766 +/- Defactinib for the Treatment of Low-Grade Serous Ovarian Cancer and KRAS G12V Mutant Non-Small Cell Lung Cancer Company Secured up to $150 Million in Non-Dilutive Funding from Oxf...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Verastem recently reported their Q4 and full-year 2021 earnings that revealed substantial headway in their pipeline and on the balance sheet. Verastem secured up to $150M in non-dilutive funding from Oxford Finance. Now, the company expects their cash runway to last through 2025. ...
News, Short Squeeze, Breakout and More Instantly...
Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the pricing of an underwritten public offering of 13,333,334 shares of its common stock and accompanying warrants to purchase up to 13,333,334 shares of it...
Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of common stock, as well as pre-funded warrants t...
GenFleet’s IND in China was cleared in June 2024; this is the first discovery program from the collaboration Verastem announced in 2023 to advance into human clinical trials Verastem plans to initiate development studies outside of China after evaluating initial dose escalation dat...